SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3s95'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1HWI_C_115C4_1 (HMG-COA REDUCTASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	4 / 7	ARG A 608 VAL A 438 SER A 439 ASN A 473	None	1.21A	1hwiC-3s95A: undetectable	1hwiC-3s95A: 22.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1HWI_D_115D3_2 (HMG-COA REDUCTASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	4 / 7	ARG A 608 VAL A 438 SER A 439 ASN A 473	None	1.21A	1hwiD-3s95A: undetectable	1hwiD-3s95A: 22.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	1.06A	1iepA-3s95A: 24.1	1iepA-3s95A: 31.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	4 / 6	LEU A 345 LYS A 368 VAL A 387 ARG A 459	STU A 1 (-3.8A) STU A 1 (-3.1A) None None	1.00A	1opjB-3s95A: 23.6	1opjB-3s95A: 31.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1QOM_A_H4BA902_1 (NITRIC OXIDE SYNTHASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	ARG A 422 ILE A 537 TRP A 515	TRS A 640 (-3.9A) None None	1.12A	1qomA-3s95A: undetectable	1qomA-3s95A: 22.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1QW6_A_H4BA901_1 (NITRIC-OXIDE SYNTHASE, BRAIN)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	ARG A 555 VAL A 538 TRP A 515	GOL A 4 ( 3.9A) None None	1.24A	1qw6A-3s95A: undetectable	1qw6A-3s95A: 21.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1QWC_A_H4BA901_1 (NITRIC-OXIDE SYNTHASE, BRAIN)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	ARG A 555 VAL A 538 TRP A 515	GOL A 4 ( 3.9A) None None	1.22A	1qwcA-3s95A: undetectable	1qwcA-3s95A: 21.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 12	GLU A 384 LEU A 397 THR A 413 LEU A 451 HIS A 458	STU A 1 (-3.7A) STU A 1 (-4.6A) STU A 1 (-3.9A) None None	0.62A	1uwhA-3s95A: 26.3	1uwhA-3s95A: 29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 12	LYS A 368 GLU A 384 LEU A 397 THR A 413 LEU A 451 HIS A 458	STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-4.6A) STU A 1 (-3.9A) None None	0.70A	1uwhB-3s95A: 26.1	1uwhB-3s95A: 29.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1VAG_A_H4BA901_1 (NITRIC-OXIDE SYNTHASE, BRAIN)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	ARG A 555 VAL A 538 TRP A 515	GOL A 4 ( 3.9A) None None	1.21A	1vagA-3s95A: undetectable	1vagA-3s95A: 21.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 LYS A 368 GLU A 384 THR A 413 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.81A	2gqgA-3s95A: 20.2	2gqgA-3s95A: 31.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.70A	2gqgA-3s95A: 20.2	2gqgA-3s95A: 31.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	4 / 6	LEU A 345 LYS A 368 VAL A 387 MET A 388	STU A 1 (-3.8A) STU A 1 (-3.1A) None None	0.88A	2hyyC-3s95A: 24.5	2hyyC-3s95A: 30.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 LYS A 368 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.99A	2itoA-3s95A: 27.1	2itoA-3s95A: 27.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2OIQ_A_STIA1001_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.96A	2oiqA-3s95A: 24.8	2oiqA-3s95A: 35.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WGJ_A_VGHA2346_1 (HEPATOCYTE GROWTH FACTOR RECEPTOR)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 12	GLY A 346 LEU A 397 TYR A 415 GLY A 419 ALA A 477 ASP A 478	STU A 1 (-3.4A) STU A 1 (-4.6A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 ( 4.1A) STU A 1 ( 4.2A)	0.75A	2wgjA-3s95A: 24.4	2wgjA-3s95A: 30.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y6O_A_1N1A1892_1 (EPHRIN TYPE-A RECEPTOR 4)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467	STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.84A	2y6oA-3s95A: 20.1	2y6oA-3s95A: 29.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZBZ_A_VDXA501_1 (CYTOCHROME P450-SU1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 11	THR A 413 VAL A 387 MET A 454 ILE A 456 ALA A 477	STU A 1 (-3.9A) None None None STU A 1 ( 4.1A)	1.11A	2zbzA-3s95A: undetectable	2zbzA-3s95A: 21.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 LYS A 368 GLU A 384 THR A 413 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.78A	2zvaA-3s95A: 27.5	2zvaA-3s95A: 30.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.69A	2zvaA-3s95A: 27.5	2zvaA-3s95A: 30.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_B_1N1B1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.77A	3g5dB-3s95A: 26.5	3g5dB-3s95A: 35.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	1.07A	3ms9B-3s95A: 23.6	3ms9B-3s95A: 31.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 12	LEU A 345 GLU A 384 MET A 388 THR A 413 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	1.13A	3mssA-3s95A: 24.0	3mssA-3s95A: 31.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	1.09A	3mssD-3s95A: 23.8	3mssD-3s95A: 31.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3NW2_A_H4BA902_1 (NITRIC OXIDE SYNTHASE, INDUCIBLE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	ARG A 422 ILE A 537 TRP A 515	TRS A 640 (-3.9A) None None	1.13A	3nw2A-3s95A: undetectable	3nw2A-3s95A: 21.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3NW2_B_H4BB902_1 (NITRIC OXIDE SYNTHASE, INDUCIBLE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	ARG A 422 ILE A 537 TRP A 515	TRS A 640 (-3.9A) None None	1.10A	3nw2B-3s95A: undetectable	3nw2B-3s95A: 21.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_B_STIB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 VAL A 387 MET A 388 THR A 413 TYR A 415 LEU A 467 ALA A 477	STU A 1 (-3.1A) None None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.89A	3oezB-3s95A: 24.9	3oezB-3s95A: 34.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 9	LEU A 345 LYS A 368 VAL A 387 ARG A 459 LEU A 467 VAL A 476	STU A 1 (-3.8A) STU A 1 (-3.1A) None None STU A 1 (-4.6A) None	1.04A	3oxzA-3s95A: 25.0	3oxzA-3s95A: 30.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_A_1N1A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	9 / 12	LEU A 345 LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.86A	3qlgA-3s95A: 25.8	3qlgA-3s95A: 34.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LEU A 345 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.76A	3qlgB-3s95A: 26.4	3qlgB-3s95A: 34.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 MET A 388 THR A 413 TYR A 415 ILE A 416 GLY A 419 LEU A 467	STU A 1 (-3.8A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-4.3A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.61A	3sxrA-3s95A: 25.6	3sxrA-3s95A: 30.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 MET A 388 THR A 413 TYR A 415 ILE A 416 GLY A 419 LEU A 467	STU A 1 (-3.8A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-4.3A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.61A	3sxrB-3s95A: 25.2	3sxrB-3s95A: 30.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZOS_A_0LIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	9 / 12	LEU A 345 LYS A 368 GLU A 384 THR A 413 LEU A 451 HIS A 458 ARG A 459 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-3.9A) None None None STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.94A	3zosA-3s95A: 24.1	3zosA-3s95A: 29.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ZOS_B_0LIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LYS A 368 GLU A 384 THR A 413 LEU A 451 HIS A 458 ARG A 459 LEU A 467 ALA A 477	STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-3.9A) None None None STU A 1 (-4.6A) STU A 1 ( 4.1A)	1.01A	3zosB-3s95A: 24.2	3zosB-3s95A: 29.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_A_0LIA1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 GLU A 384 LEU A 397 THR A 413 HIS A 458 LEU A 467 ALA A 477	STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-4.6A) STU A 1 (-3.9A) None STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.75A	4c8bA-3s95A: 25.4	4c8bA-3s95A: 23.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_B_0LIB1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 GLU A 384 LEU A 397 THR A 413 HIS A 458 LEU A 467 ALA A 477	STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-4.6A) STU A 1 (-3.9A) None STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.79A	4c8bB-3s95A: 25.2	4c8bB-3s95A: 23.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MJ8_A_SPMA202_1 (SPERMIDINE N1-ACETYLTRANSFERASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	4 / 8	ILE A 354 GLU A 369 GLN A 352 LEU A 370	None	0.85A	4mj8A-3s95A: undetectable	4mj8A-3s95A: 19.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LEU A 345 LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 ASP A 478	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 ( 4.2A)	0.80A	4mxoA-3s95A: 26.9	4mxoA-3s95A: 34.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LEU A 345 LYS A 368 GLU A 384 THR A 413 TYR A 415 GLY A 419 LEU A 467 ASP A 478	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.2A)	0.82A	4mxoB-3s95A: 27.0	4mxoB-3s95A: 34.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467	STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.75A	4mxxA-3s95A: 20.3	4mxxA-3s95A: 34.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0S_A_ADNA500_1 (AURORA KINASE A)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 11	LEU A 345 GLY A 346 LYS A 368 LEU A 397 THR A 420 ASN A 465 LEU A 467	STU A 1 (-3.8A) STU A 1 (-3.4A) STU A 1 (-3.1A) STU A 1 (-4.6A) STU A 1 (-4.6A) STU A 1 (-4.5A) STU A 1 (-4.6A)	0.85A	4o0sA-3s95A: 26.9	4o0sA-3s95A: 27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 LYS A 368 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.79A	4otwA-3s95A: 23.6	4otwA-3s95A: 25.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477 ASP A 478	STU A 1 (-3.8A) STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A) STU A 1 ( 4.2A)	0.77A	4otwA-3s95A: 23.6	4otwA-3s95A: 25.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QB9_D_PARD500_1 (ENHANCED INTRACELLULAR SURVIVAL PROTEIN)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	4 / 8	PHE A 597 SER A 534 GLU A 384 ASP A 478	None None STU A 1 (-3.7A) STU A 1 ( 4.2A)	1.31A	4qb9D-3s95A: undetectable	4qb9D-3s95A: 22.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QRC_A_0LIA802_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 12	GLU A 384 MET A 388 LEU A 451 ARG A 459 ALA A 477	STU A 1 (-3.7A) None None None STU A 1 ( 4.1A)	1.02A	4qrcA-3s95A: 26.1	4qrcA-3s95A: 29.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RTB_A_SAMA501_1 (HYDG PROTEIN)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	GLU A 630 ARG A 633 GLN A 623	None	0.88A	4rtbA-3s95A: undetectable	4rtbA-3s95A: 20.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4UXQ_A_0LIA1752_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 12	LEU A 345 LEU A 451 HIS A 458 LEU A 467 ALA A 477	STU A 1 (-3.8A) None None STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.26A	4uxqA-3s95A: 25.9	4uxqA-3s95A: 30.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_A_0LIA1772_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 8	LYS A 368 MET A 388 TYR A 415 ARG A 459 LEU A 467	STU A 1 (-3.1A) None STU A 1 (-4.7A) None STU A 1 (-4.6A)	1.24A	4v04A-3s95A: 25.4	4v04A-3s95A: 30.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_B_0LIB1771_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 10	LEU A 345 LYS A 368 MET A 388 TYR A 415 ARG A 459 LEU A 467	STU A 1 (-3.8A) STU A 1 (-3.1A) None STU A 1 (-4.7A) None STU A 1 (-4.6A)	1.17A	4v04B-3s95A: 26.0	4v04B-3s95A: 30.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LEU A 345 LYS A 368 GLU A 384 MET A 388 THR A 413 GLY A 419 LEU A 467	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.97A	4wkqA-3s95A: 26.8	4wkqA-3s95A: 28.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	9 / 12	LEU A 345 LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.76A	4xliA-3s95A: 27.5	4xliA-3s95A: 31.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	9 / 12	LEU A 345 LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.67A	4xliB-3s95A: 27.2	4xliB-3s95A: 31.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 12	LYS A 368 LEU A 397 THR A 413 ASP A 478 PHE A 479	STU A 1 (-3.1A) STU A 1 (-4.6A) STU A 1 (-3.9A) STU A 1 ( 4.2A) None	0.84A	4xv2B-3s95A: 25.1	4xv2B-3s95A: 29.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BVW_A_1N1A1009_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LEU A 345 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.85A	5bvwA-3s95A: 24.5	5bvwA-3s95A: 28.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BVW_A_1N1A1009_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	8 / 12	LEU A 345 LYS A 368 GLU A 384 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.68A	5bvwA-3s95A: 24.5	5bvwA-3s95A: 28.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5DV4_A_NMYA601_1 (CCR4-NOT TRANSCRIPTION COMPLEX SUBUNIT 6-LIKE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 12	LEU A 391 ASN A 462 ASP A 531 ILE A 457 HIS A 452	None	1.21A	5dv4A-3s95A: undetectable	5dv4A-3s95A: 22.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5F9Z_B_HFGB703_0 (AMINOACYL-TRNA SYNTHETASE)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 12	LEU A 600 PHE A 535 VAL A 532 PRO A 595 GLY A 627	None None None GOL A 6 ( 4.6A) None	1.33A	5f9zB-3s95A: undetectable	5f9zB-3s95A: 20.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 12	LYS A 368 GLU A 384 LEU A 397 THR A 413 LEU A 451 HIS A 458	STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-4.6A) STU A 1 (-3.9A) None None	0.62A	5hi2A-3s95A: 25.7	5hi2A-3s95A: 29.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9X_A_DB8A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 12	LYS A 368 GLU A 384 THR A 413 TYR A 415 GLY A 419 LEU A 467	STU A 1 (-3.1A) STU A 1 (-3.7A) STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.72A	5i9xA-3s95A: 26.4	5i9xA-3s95A: 29.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5I9Y_A_1N1A1001_1 (EPHRIN TYPE-A RECEPTOR 2)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	7 / 12	LYS A 368 GLU A 384 MET A 388 THR A 413 TYR A 415 GLY A 419 LEU A 467	STU A 1 (-3.1A) STU A 1 (-3.7A) None STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A)	0.75A	5i9yA-3s95A: 19.1	5i9yA-3s95A: 29.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IEN_B_VDYB201_1 (CDL2.2)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	5 / 10	PRO A 433 VAL A 468 ILE A 542 LEU A 421 LEU A 607	None	1.13A	5ienB-3s95A: undetectable	5ienB-3s95A: 20.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	6 / 12	LEU A 345 GLU A 384 MET A 388 TYR A 415 GLY A 419 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.7A) None STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 ( 4.1A)	0.80A	5zv2A-3s95A: 25.0	5zv2A-3s95A: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	LYS A 368 LEU A 467 ASP A 478	STU A 1 (-3.1A) STU A 1 (-4.6A) STU A 1 ( 4.2A)	0.76A	5zv2A-3s95A: 25.0	5zv2A-3s95A: 14.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	3 / 3	TYR A 415 LEU A 467 ASP A 478	STU A 1 (-4.7A) STU A 1 (-4.6A) STU A 1 ( 4.2A)	0.64A	5zv2B-3s95A: 25.1	5zv2B-3s95A: 14.33

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1HWI_C_115C4_1","HMG-COA REDUCTASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",4,"ARG A 608;VAL A 438;SER A 439;ASN A 473","None","1.21A","1hwiC-3s95A:undetectable","1hwiC-3s95A:22.12"],["1HWI_D_115D3_2","HMG-COA REDUCTASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",4,"ARG A 608;VAL A 438;SER A 439;ASN A 473","None","1.21A","1hwiD-3s95A:undetectable","1hwiD-3s95A:22.12"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","1.06A","1iepA-3s95A:24.1","1iepA-3s95A:31.37"],["1OPJ_B_STIB4_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",4,"LEU A 345;LYS A 368;VAL A 387;ARG A 459","STU A   1 (-3.8A);STU A   1 (-3.1A);None;None","1.00A","1opjB-3s95A:23.6","1opjB-3s95A:31.37"],["1QOM_A_H4BA902_1","NITRIC OXIDE SYNTHASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"ARG A 422;ILE A 537;TRP A 515","TRS A 640 (-3.9A);None;None","1.12A","1qomA-3s95A:undetectable","1qomA-3s95A:22.00"],["1QW6_A_H4BA901_1","NITRIC-OXIDE SYNTHASE, BRAIN","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"ARG A 555;VAL A 538;TRP A 515","GOL A   4 ( 3.9A);None;None","1.24A","1qw6A-3s95A:undetectable","1qw6A-3s95A:21.14"],["1QWC_A_H4BA901_1","NITRIC-OXIDE SYNTHASE, BRAIN","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"ARG A 555;VAL A 538;TRP A 515","GOL A   4 ( 3.9A);None;None","1.22A","1qwcA-3s95A:undetectable","1qwcA-3s95A:21.14"],["1UWH_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"GLU A 384;LEU A 397;THR A 413;LEU A 451;HIS A 458","STU A   1 (-3.7A);STU A   1 (-4.6A);STU A   1 (-3.9A);None;None","0.62A","1uwhA-3s95A:26.3","1uwhA-3s95A:29.57"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"LYS A 368;GLU A 384;LEU A 397;THR A 413;LEU A 451;HIS A 458","STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-4.6A);STU A   1 (-3.9A);None;None","0.70A","1uwhB-3s95A:26.1","1uwhB-3s95A:29.57"],["1VAG_A_H4BA901_1","NITRIC-OXIDE SYNTHASE, BRAIN","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"ARG A 555;VAL A 538;TRP A 515","GOL A   4 ( 3.9A);None;None","1.21A","1vagA-3s95A:undetectable","1vagA-3s95A:21.14"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;LYS A 368;GLU A 384;THR A 413;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.81A","2gqgA-3s95A:20.2","2gqgA-3s95A:31.06"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.70A","2gqgA-3s95A:20.2","2gqgA-3s95A:31.06"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",4,"LEU A 345;LYS A 368;VAL A 387;MET A 388","STU A   1 (-3.8A);STU A   1 (-3.1A);None;None","0.88A","2hyyC-3s95A:24.5","2hyyC-3s95A:30.75"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;LYS A 368;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.99A","2itoA-3s95A:27.1","2itoA-3s95A:27.79"],["2OIQ_A_STIA1001_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.96A","2oiqA-3s95A:24.8","2oiqA-3s95A:35.14"],["2WGJ_A_VGHA2346_1","HEPATOCYTE GROWTH FACTOR RECEPTOR","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"GLY A 346;LEU A 397;TYR A 415;GLY A 419;ALA A 477;ASP A 478","STU A   1 (-3.4A);STU A   1 (-4.6A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 ( 4.1A);STU A   1 ( 4.2A)","0.75A","2wgjA-3s95A:24.4","2wgjA-3s95A:30.40"],["2Y6O_A_1N1A1892_1","EPHRIN TYPE-A RECEPTOR 4","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467","STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.84A","2y6oA-3s95A:20.1","2y6oA-3s95A:29.72"],["2ZBZ_A_VDXA501_1","CYTOCHROME P450-SU1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"THR A 413;VAL A 387;MET A 454;ILE A 456;ALA A 477","STU A   1 (-3.9A);None;None;None;STU A   1 ( 4.1A)","1.11A","2zbzA-3s95A:undetectable","2zbzA-3s95A:21.82"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;LYS A 368;GLU A 384;THR A 413;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.78A","2zvaA-3s95A:27.5","2zvaA-3s95A:30.37"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.69A","2zvaA-3s95A:27.5","2zvaA-3s95A:30.37"],["3G5D_B_1N1B1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.77A","3g5dB-3s95A:26.5","3g5dB-3s95A:35.14"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","1.07A","3ms9B-3s95A:23.6","3ms9B-3s95A:31.37"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"LEU A 345;GLU A 384;MET A 388;THR A 413;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","1.13A","3mssA-3s95A:24.0","3mssA-3s95A:31.37"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","1.09A","3mssD-3s95A:23.8","3mssD-3s95A:31.37"],["3NW2_A_H4BA902_1","NITRIC OXIDE SYNTHASE, INDUCIBLE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"ARG A 422;ILE A 537;TRP A 515","TRS A 640 (-3.9A);None;None","1.13A","3nw2A-3s95A:undetectable","3nw2A-3s95A:21.72"],["3NW2_B_H4BB902_1","NITRIC OXIDE SYNTHASE, INDUCIBLE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"ARG A 422;ILE A 537;TRP A 515","TRS A 640 (-3.9A);None;None","1.10A","3nw2B-3s95A:undetectable","3nw2B-3s95A:21.72"],["3OEZ_B_STIB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;VAL A 387;MET A 388;THR A 413;TYR A 415;LEU A 467;ALA A 477","STU A   1 (-3.1A);None;None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.89A","3oezB-3s95A:24.9","3oezB-3s95A:34.83"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"LEU A 345;LYS A 368;VAL A 387;ARG A 459;LEU A 467;VAL A 476","STU A   1 (-3.8A);STU A   1 (-3.1A);None;None;STU A   1 (-4.6A);None","1.04A","3oxzA-3s95A:25.0","3oxzA-3s95A:30.65"],["3QLG_A_1N1A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",9,"LEU A 345;LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.86A","3qlgA-3s95A:25.8","3qlgA-3s95A:34.83"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LEU A 345;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.76A","3qlgB-3s95A:26.4","3qlgB-3s95A:34.83"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;MET A 388;THR A 413;TYR A 415;ILE A 416;GLY A 419;LEU A 467","STU A   1 (-3.8A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-4.3A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.61A","3sxrA-3s95A:25.6","3sxrA-3s95A:30.13"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;MET A 388;THR A 413;TYR A 415;ILE A 416;GLY A 419;LEU A 467","STU A   1 (-3.8A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-4.3A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.61A","3sxrB-3s95A:25.2","3sxrB-3s95A:30.13"],["3ZOS_A_0LIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",9,"LEU A 345;LYS A 368;GLU A 384;THR A 413;LEU A 451;HIS A 458;ARG A 459;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-3.9A);None;None;None;STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.94A","3zosA-3s95A:24.1","3zosA-3s95A:29.13"],["3ZOS_B_0LIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LYS A 368;GLU A 384;THR A 413;LEU A 451;HIS A 458;ARG A 459;LEU A 467;ALA A 477","STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-3.9A);None;None;None;STU A   1 (-4.6A);STU A   1 ( 4.1A)","1.01A","3zosB-3s95A:24.2","3zosB-3s95A:29.13"],["4C8B_A_0LIA1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;GLU A 384;LEU A 397;THR A 413;HIS A 458;LEU A 467;ALA A 477","STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-4.6A);STU A   1 (-3.9A);None;STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.75A","4c8bA-3s95A:25.4","4c8bA-3s95A:23.81"],["4C8B_B_0LIB1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;GLU A 384;LEU A 397;THR A 413;HIS A 458;LEU A 467;ALA A 477","STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-4.6A);STU A   1 (-3.9A);None;STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.79A","4c8bB-3s95A:25.2","4c8bB-3s95A:23.81"],["4MJ8_A_SPMA202_1","SPERMIDINE N1-ACETYLTRANSFERASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",4,"ILE A 354;GLU A 369;GLN A 352;LEU A 370","None","0.85A","4mj8A-3s95A:undetectable","4mj8A-3s95A:19.42"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LEU A 345;LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;ASP A 478","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 ( 4.2A)","0.80A","4mxoA-3s95A:26.9","4mxoA-3s95A:34.83"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LEU A 345;LYS A 368;GLU A 384;THR A 413;TYR A 415;GLY A 419;LEU A 467;ASP A 478","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.2A)","0.82A","4mxoB-3s95A:27.0","4mxoB-3s95A:34.83"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467","STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.75A","4mxxA-3s95A:20.3","4mxxA-3s95A:34.53"],["4O0S_A_ADNA500_1","AURORA KINASE A","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;GLY A 346;LYS A 368;LEU A 397;THR A 420;ASN A 465;LEU A 467","STU A   1 (-3.8A);STU A   1 (-3.4A);STU A   1 (-3.1A);STU A   1 (-4.6A);STU A   1 (-4.6A);STU A   1 (-4.5A);STU A   1 (-4.6A)","0.85A","4o0sA-3s95A:26.9","4o0sA-3s95A:27.52"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;LYS A 368;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.79A","4otwA-3s95A:23.6","4otwA-3s95A:25.22"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477;ASP A 478","STU A   1 (-3.8A);STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A);STU A   1 ( 4.2A)","0.77A","4otwA-3s95A:23.6","4otwA-3s95A:25.22"],["4QB9_D_PARD500_1","ENHANCED INTRACELLULAR SURVIVAL PROTEIN","3s95","LIM DOMAIN KINASE 1","Homo sapiens",4,"PHE A 597;SER A 534;GLU A 384;ASP A 478","None;None;STU A   1 (-3.7A);STU A   1 ( 4.2A)","1.31A","4qb9D-3s95A:undetectable","4qb9D-3s95A:22.62"],["4QRC_A_0LIA802_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"GLU A 384;MET A 388;LEU A 451;ARG A 459;ALA A 477","STU A   1 (-3.7A);None;None;None;STU A   1 ( 4.1A)","1.02A","4qrcA-3s95A:26.1","4qrcA-3s95A:29.64"],["4RTB_A_SAMA501_1","HYDG PROTEIN","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"GLU A 630;ARG A 633;GLN A 623","None","0.88A","4rtbA-3s95A:undetectable","4rtbA-3s95A:20.74"],["4UXQ_A_0LIA1752_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"LEU A 345;LEU A 451;HIS A 458;LEU A 467;ALA A 477","STU A   1 (-3.8A);None;None;STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.26A","4uxqA-3s95A:25.9","4uxqA-3s95A:30.17"],["4V04_A_0LIA1772_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"LYS A 368;MET A 388;TYR A 415;ARG A 459;LEU A 467","STU A   1 (-3.1A);None;STU A   1 (-4.7A);None;STU A   1 (-4.6A)","1.24A","4v04A-3s95A:25.4","4v04A-3s95A:30.50"],["4V04_B_0LIB1771_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"LEU A 345;LYS A 368;MET A 388;TYR A 415;ARG A 459;LEU A 467","STU A   1 (-3.8A);STU A   1 (-3.1A);None;STU A   1 (-4.7A);None;STU A   1 (-4.6A)","1.17A","4v04B-3s95A:26.0","4v04B-3s95A:30.50"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LEU A 345;LYS A 368;GLU A 384;MET A 388;THR A 413;GLY A 419;LEU A 467","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.97A","4wkqA-3s95A:26.8","4wkqA-3s95A:28.12"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",9,"LEU A 345;LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.76A","4xliA-3s95A:27.5","4xliA-3s95A:31.45"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",9,"LEU A 345;LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.67A","4xliB-3s95A:27.2","4xliB-3s95A:31.45"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"LYS A 368;LEU A 397;THR A 413;ASP A 478;PHE A 479","STU A   1 (-3.1A);STU A   1 (-4.6A);STU A   1 (-3.9A);STU A   1 ( 4.2A);None","0.84A","4xv2B-3s95A:25.1","4xv2B-3s95A:29.62"],["5BVW_A_1N1A1009_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LEU A 345;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.85A","5bvwA-3s95A:24.5","5bvwA-3s95A:28.42"],["5BVW_A_1N1A1009_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",8,"LEU A 345;LYS A 368;GLU A 384;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.68A","5bvwA-3s95A:24.5","5bvwA-3s95A:28.42"],["5DV4_A_NMYA601_1","CCR4-NOT TRANSCRIPTION COMPLEX SUBUNIT 6-LIKE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"LEU A 391;ASN A 462;ASP A 531;ILE A 457;HIS A 452","None","1.21A","5dv4A-3s95A:undetectable","5dv4A-3s95A:22.06"],["5F9Z_B_HFGB703_0","AMINOACYL-TRNA SYNTHETASE","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"LEU A 600;PHE A 535;VAL A 532;PRO A 595;GLY A 627","None;None;None;GOL A   6 ( 4.6A);None","1.33A","5f9zB-3s95A:undetectable","5f9zB-3s95A:20.97"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"LYS A 368;GLU A 384;LEU A 397;THR A 413;LEU A 451;HIS A 458","STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-4.6A);STU A   1 (-3.9A);None;None","0.62A","5hi2A-3s95A:25.7","5hi2A-3s95A:29.47"],["5I9X_A_DB8A1001_1","EPHRIN TYPE-A RECEPTOR 2","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"LYS A 368;GLU A 384;THR A 413;TYR A 415;GLY A 419;LEU A 467","STU A   1 (-3.1A);STU A   1 (-3.7A);STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.72A","5i9xA-3s95A:26.4","5i9xA-3s95A:29.81"],["5I9Y_A_1N1A1001_1","EPHRIN TYPE-A RECEPTOR 2","3s95","LIM DOMAIN KINASE 1","Homo sapiens",7,"LYS A 368;GLU A 384;MET A 388;THR A 413;TYR A 415;GLY A 419;LEU A 467","STU A   1 (-3.1A);STU A   1 (-3.7A);None;STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A)","0.75A","5i9yA-3s95A:19.1","5i9yA-3s95A:29.81"],["5IEN_B_VDYB201_1","CDL2.2","3s95","LIM DOMAIN KINASE 1","Homo sapiens",5,"PRO A 433;VAL A 468;ILE A 542;LEU A 421;LEU A 607","None","1.13A","5ienB-3s95A:undetectable","5ienB-3s95A:20.97"],["5ZV2_A_LEVA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",6,"LEU A 345;GLU A 384;MET A 388;TYR A 415;GLY A 419;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.7A);None;STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 ( 4.1A)","0.80A","5zv2A-3s95A:25.0","5zv2A-3s95A:14.33"],["5ZV2_A_LEVA801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"LYS A 368;LEU A 467;ASP A 478","STU A   1 (-3.1A);STU A   1 (-4.6A);STU A   1 ( 4.2A)","0.76A","5zv2A-3s95A:25.0","5zv2A-3s95A:14.33"],["5ZV2_B_LEVB801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1","3s95","LIM DOMAIN KINASE 1","Homo sapiens",3,"TYR A 415;LEU A 467;ASP A 478","STU A   1 (-4.7A);STU A   1 (-4.6A);STU A   1 ( 4.2A)","0.64A","5zv2B-3s95A:25.1","5zv2B-3s95A:14.33"]]